Valion Bio Approves Board Authority for Reverse Stock Split (1-for-5 to 1-for-50)

What Happened
Valion Bio, Inc. (VBIO) filed an 8-K reporting that at a virtual Special Meeting on August 14, 2026, stockholders approved giving the board discretionary authority to amend the company’s certificate of incorporation to effect a reverse stock split of its common stock at a ratio of not less than 1-for-5 and not greater than 1-for-50. The board may implement the reverse split at any time within 12 months from the Special Meeting date, without further stockholder approval.

Key Details

• Record date: July 7, 2026; outstanding common shares on that date: 4,151,259.
• Meeting attendance: 2,001,335 shares represented (approx. 48.21% of outstanding common stock), constituting a quorum.
• Proposal 1 (reverse split authority) vote: For 1,243,530; Against 697,127; Abstentions 60,678.
• Proposal 2 (authority to adjourn if needed) vote: For 1,242,980; Against 686,908; Abstentions 71,447. The chair did not adjourn the meeting because Proposal 1 was approved.
• Holders of Series A, B and C non‑voting convertible preferred stock were not entitled to vote.

Why It Matters
The board now has the power to reduce the number of outstanding common shares by between 5x and 50x (depending on the ratio it chooses) within the next year, without another stockholder vote. A reverse split will proportionally reduce share counts and increase the per‑share price (and will change metrics like shares outstanding and per‑share market price); investors should watch for a future company announcement specifying whether the board implements a split, the chosen ratio, and the effective date.